SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2006 / Cilt: 30 - Sayı: 1

Synthesis and Anticancer Evaluation of Some New Unsymmetrical 3,5-Diaryl-4H-1,2,4-Triazole Derivatives

Olcay BEKİRCAN
Bahittin KAHVECİ
Murat KÜÇÜK
Pages
29–40
Publication Date
2006-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Compound 17, chosen for its higher anticancer activity in the preliminary tests with the cancer cell lines of MCF7, NCI-H460, and SF-268, exhibited remarkable anticancer potential in screening tests with 60 human cancer cell lines.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A series of 4-arylidenamino-4H-1,2,4-triazole derivatives (3-11) were synthesized from the treatment of 4-amino-4H-1,2,4-triazoles (2) with certain aldehydes.
📊
Key Findings & Data:Compounds 3-11 were reduced with NaBH4 to afford the corresponding 4-arylmethylenamino-4H-1,2,4-triazoles (12-20).
💡
Conclusion & Impact:Compound 17, chosen for its higher anticancer activity in the preliminary tests with the cancer cell lines of MCF7, NCI-H460, and SF-268, exhibited remarkable anticancer potential in screening tests with 60 human cancer cell lines.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:4H-1 · 4-Triazoles · 4-Amino-4H-1

Abstract

A series of 4-arylidenamino-4H-1,2,4-triazole derivatives (3-11) were synthesized from the treatment of 4-amino-4H-1,2,4-triazoles (2) with certain aldehydes. Compounds 3-11 were reduced with NaBH4 to afford the corresponding 4-arylmethylenamino-4H-1,2,4-triazoles (12-20). Compounds 1-10 and 12-19 were characterized by elemental analyses and 1H NMR, 13C NMR, IR and UV spectral data. Compounds 11 and 20 were characterized by 1H NMR, 13C NMR, IR and mass spectral data. Compounds 14, 16, 17, and 18 were tested for anticancer activities. Compound 17, chosen for its higher anticancer activity in the preliminary tests with the cancer cell lines of MCF7, NCI-H460, and SF-268, exhibited remarkable anticancer potential in screening tests with 60 human cancer cell lines.

Özet

A series of 4-arylidenamino-4H-1,2,4-triazole derivatives (3-11) were synthesized from the treatment of 4-amino-4H-1,2,4-triazoles (2) with certain aldehydes. Compounds 3-11 were reduced with NaBH4 to afford the corresponding 4-arylmethylenamino-4H-1,2,4-triazoles (12-20). Compounds 1-10 and 12-19 were characterized by elemental analyses and 1H NMR, 13C NMR, IR and UV spectral data. Compounds 11 and 20 were characterized by 1H NMR, 13C NMR, IR and mass spectral data. Compounds 14, 16, 17, and 18 were tested for anticancer activities. Compound 17, chosen for its higher anticancer activity in the preliminary tests with the cancer cell lines of MCF7, NCI-H460, and SF-268, exhibited remarkable anticancer potential in screening tests with 60 human cancer cell lines.

🔖

Cite This Article

BEKİRCAN, O., KAHVECİ, B., KÜÇÜK, M. (2006). Synthesis and Anticancer Evaluation of Some New Unsymmetrical 3,5-Diaryl-4H-1,2,4-Triazole Derivatives. Turkish Journal of Chemistry, Cilt: 30 - Sayı: 1, 29–40. https://ajindex.com/articles/220584

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. O.G. Todoulou, A.E. Papadaki-Valiraki, S. Ikeda and E.D. Clercq, Eur. J. Med. Chem. 29, 611-620 (1994) ˙I. K¨u¸c¨ukg¨uzel, S¸.G. K¨u¸c¨ukg¨uzel, S. Rollas, G. ¨Ot¨uk-Sanı¸s, O. ¨Ozdemir, ˙I. Bayrak, T. Altu˘g and J.P. Stables, Il Farmaco 59, 893-901 (2004).
  2. S. Rollas, N. Kalyoncuoglu, D. Sur-Altiner and Y. Yegenoglu, Pharmazie 48, 308-309 (1993).
  3. F. Malbec, R. Milcent and P. Vicart, J. Heterocycl. Chem. 21, 1769-1775 (1984).
  4. B. Modzelewska and J. Kalabun, Pharmazie 54, 503 (1999). N. G¨ulerman, S. Rollas, M. Kiraz, A.C. Ekinci and A. Vidin, Il Farmaco 52, 691- 695 (1997). A.A. ˙Ikizler, A. ˙Ikizler, M. Serdar and N. Yıldırım, Acta Pol. Pharm. Drug Res. 54, 363-369 (1997). O. Bekircan and N. G¨umr¨uk¸c¨uoglu, Indian J. Chem. 44B, 2107-2113 (2005). B. Kahveci and A.A. ˙Ikizler, Acta Pol. Pharm. Drug Res. 57, 119-124 (2000).
  5. N. Demirbas, R. Ugurluoglu and A. Demirbas, Bioorg. Med. Chem. 10, 3717-3723 (2002).
  6. B. Kahveci, O. Bekircan, M. Serdar and A.A. Ikizler, Indian J. Chem. 42B, 1527-1530 (2003). N. Demirba¸s, R. U˘gurluo˘glu, A. Demirbas and K. Sancak, Eur. J. Med. Chem. 39, 793 (2004). N. Demirba¸s and R. U˘gurluo˘glu, Turk. J. Chem. 28, 679-690 (2004). M.P. Grammaticakis and M.G. Champetier, C.R. Acad. Sci. Paris 271, 940-943 (1970).
  7. R. Milcent and C. Redeuilh, J. Heterocycl. Chem. 14, 53-58 (1977).
  8. Z. Hovii, T. Sakai and T. Inoi, J. Pharm. Soc. Japan 75, 1161-1167 (1955).
  9. J.H. Billman and A.C. Diesing, J. Org. Chem. 22, 1068-1074 (1957).
  10. A.R. Katritzky and K.S. Laurenzo, J. Org. Chem. 53, 3978-3982 (1988). B. Kahveci and A.A. ˙Ikizler, Turk. J. Chem. 24, 343-350 (2000).
  11. G.D. Gray and E. Wickstrom, Biotechniques 21, 780-782 (1996).
  12. M.C. Alley, D.A. Scudiero, P.A. Monks, M. L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker and M.R. Boyd, Cancer Res. 48, 589-601 (1988).
  13. M.R. Grever, S.A. Schepartz and B.A. Chabner, Semin. Oncol. 19, 622-638 (1992).
  14. M.R. Boyd and K.D. Paull, Drug Develop. Res. 34, 91-109 (1995).
  15. W. Zielinski and W. Czardybon, Chem. Heterocycl. Comp. 37, 1107-1110 (2001).
  16. M. Traisnel, B. Mernari and H. Elattari, J. Heterocycl. Chem. 36, 149-152 (1999).
  17. S. Brooker, Coordin. Chem. Rev. 241, 119-132 (2003).
  18. Y. Ikemi, N. Hayashi, A. Kakehi and K. Matsumoto, Heterocycl. Commun. 8, 439-442 (2002).
  19. H. Koshima, M. Hamada, M. Tani, S. Iwasaki and F. Sato, Heterocycles 57, 2145-2148 (2002).
  20. F. Bentiss, M. Lagrenee, B. Elmehdi, B. Mernari, M. Traisnel and H. Vezin, Corrosion 58, 399-407 (2002).
  21. F. Bentiss, M. Lagrenee, H. Ve